Clinical Trial Update: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy, tolerability, and pharmacokinetics of MYMD1 for chronic inflammation-related sarcopenia and frailty has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aging
• Frailty
• Sarcopenia

Drugs mentioned

• MYMD1 (MYMD1)

Snippet

Sponsor: TNF Pharmaceuticals, Inc. | Conditions: Sarcopenia, Frailty | Phase 2 | Status: COMPLETED